Last update 27 Jul 2026

Biogen U.S. Corp.

Subsidiary Company|2001|Massachusetts, United States

Overview

Tags

Nervous System Diseases
Other Diseases
Congenital Disorders
Monoclonal antibody
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Neoplasms1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug1
Monoclonal antibody1
Top 5 TargetCount
APP(Beta amyloid A4 protein)1
CDC20 x Nrf21

Related

2
Drugs associated with Biogen U.S. Corp.
Omaveloxolone
Target
CDC20 x Nrf2
Mechanism
CDC20 inhibitors [+1]
Active Org.
Biogen U.S. Corp. [+7]
Originator Org.
Reata Pharmaceuticals, Inc.Reata Pharmaceuticals, Inc.
Active Indication
Friedreich Ataxia [+3]
Inactive Indication
Advanced Malignant Solid Neoplasm [+14]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date28 Feb 2023
Lecanemab
Target
APP
Mechanism
APP inhibitors
Active Org.
Eisai Co., Ltd.Eisai Co., Ltd. [+6]
Originator Org.
BioArctic ABBioArctic AB
Active Indication
Mild dementia [+5]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date06 Jan 2023
100 Clinical Results associated with Biogen U.S. Corp.
Login to view more data
0 Patents (Medical) associated with Biogen U.S. Corp.
Login to view more data
100 Deals associated with Biogen U.S. Corp.
Login to view more data
100 Translational Medicine associated with Biogen U.S. Corp.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Omaveloxolone
 ( CDC20 x Nrf2 )		Friedreich Ataxia
More
Approved
Lecanemab
 ( APP )		Mild cognitive disorder
More
Phase 3
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free